DR. REDDY'S LAB -slide show

Dr. Reddy’s laboratories- Rohit kumar mishra 1st year MBA IBS-bangalore. : 

Dr. Reddy’s laboratories- Rohit kumar mishra 1st year MBA IBS-bangalore.

Dr. Reddy’s Laboratories is leading pharmaceutical company with presence in over 100 countries. It manufactures a range of products such as Active pharmaceutical ingredients, Generic and Branded Finished Dosages, Specialty pharmaceuticals, and Biopharmaceuticals. The company is situated at Ameerpet, Hyderabad. : 

Dr. Reddy’s Laboratories is leading pharmaceutical company with presence in over 100 countries. It manufactures a range of products such as Active pharmaceutical ingredients, Generic and Branded Finished Dosages, Specialty pharmaceuticals, and Biopharmaceuticals. The company is situated at Ameerpet, Hyderabad.

History: The company was incorporated on November 2, 1984, by Dr. Anji Reddy and his associates who were also the promoters of Standard Organics Limited. It was based on a bulk activities business he had founded in the 1970’s, in order to extend into the production of drug formulation. It was established with an initial capital outlay of $40,000 of his own backed by a bank loan for $120,000. Two years later, in 1986, it got listed in the Bombay Stock Exchange. : 

History: The company was incorporated on November 2, 1984, by Dr. Anji Reddy and his associates who were also the promoters of Standard Organics Limited. It was based on a bulk activities business he had founded in the 1970’s, in order to extend into the production of drug formulation. It was established with an initial capital outlay of $40,000 of his own backed by a bank loan for $120,000. Two years later, in 1986, it got listed in the Bombay Stock Exchange.

In 1987 obtained its 1st USFDA approval for Ibuprofen API and started its formulation operations. In 1997, it became the 1st Indian pharmaceutical company to out- license an original molecule when it licensed anti-diabetic molecule DRF 2593 to Novo Nordisk. In 2000, became the 1st Asia Pacific pharmaceutical company outside Japan, to be listed on the NEW YORK STOCK EXCHANGE. : 

In 1987 obtained its 1st USFDA approval for Ibuprofen API and started its formulation operations. In 1997, it became the 1st Indian pharmaceutical company to out- license an original molecule when it licensed anti-diabetic molecule DRF 2593 to Novo Nordisk. In 2000, became the 1st Asia Pacific pharmaceutical company outside Japan, to be listed on the NEW YORK STOCK EXCHANGE.

Vision and MissionVision: To become a discovery ruled global pharmaceutical company with a core purpose of helping people lead healthier lives.Mission: To be first Indian Pharmaceutical company that successfully takes its products from discovery to commercial launch globally. : 

Vision and MissionVision: To become a discovery ruled global pharmaceutical company with a core purpose of helping people lead healthier lives.Mission: To be first Indian Pharmaceutical company that successfully takes its products from discovery to commercial launch globally.

SWOT Analysis:Strength: - Wholly owned subsidiaries in US and Europe. Joint ventures in China and South Africa. -Market pharmaceuticals products in 115 countries. : 

SWOT Analysis:Strength: - Wholly owned subsidiaries in US and Europe. Joint ventures in China and South Africa. -Market pharmaceuticals products in 115 countries.

-Contributes to company’s high profit margin of around 34% of sales. -6120 employees worldwide including 323 are dedicated towards new drug discovery research.- Manufactures and market over 250 medicines targeting a wide range of therapies. : 

-Contributes to company’s high profit margin of around 34% of sales. -6120 employees worldwide including 323 are dedicated towards new drug discovery research.- Manufactures and market over 250 medicines targeting a wide range of therapies.

Weakness: -High amount of revenues from overseas. -Over reliance on partnerships.- Lack of resources similar to US and Europe based competitors to develop a drug to marketing stage. -Lack of patent legislation in India horns sales in its products. : 

Weakness: -High amount of revenues from overseas. -Over reliance on partnerships.- Lack of resources similar to US and Europe based competitors to develop a drug to marketing stage. -Lack of patent legislation in India horns sales in its products.

Opportunities: -Takes a molecule from its pipeline all the market place cost- effectively.- Domestic Genetic drugs market. -Buy back of the integrated drug development company from ICICI ventures and Citigroup. : 

Opportunities: -Takes a molecule from its pipeline all the market place cost- effectively.- Domestic Genetic drugs market. -Buy back of the integrated drug development company from ICICI ventures and Citigroup.

Threats: -Needs to give FDA approval for all sources and products.- Products have to pass strictly FDA trials before going to market, which can be costly and time consuming.- Competitors from US and European countries. -Lost the case against Pfizer for the use of generic form of Norvasc drug, legal cost of $10 million and loss of market opportunities. : 

Threats: -Needs to give FDA approval for all sources and products.- Products have to pass strictly FDA trials before going to market, which can be costly and time consuming.- Competitors from US and European countries. -Lost the case against Pfizer for the use of generic form of Norvasc drug, legal cost of $10 million and loss of market opportunities.

: 

Products: Active Pharmaceutical Ingredients (API)Custom Pharmaceuticals ServicesGeneric DosagesBranded Dosages (such as- Omez, Nise, Stamlo, Ciprolet, Enam, Ketorol).

Branches:It has limited branches in Hyderabad.- DBR Diagnostic Centre, Kapra.-Dr. Reddy’s Laboratories Ltd, Kapra.-Pragathi Diagnostic , Kapra.- SL Diagnostic and Speciality Clinic, Kapra. : 

Branches:It has limited branches in Hyderabad.- DBR Diagnostic Centre, Kapra.-Dr. Reddy’s Laboratories Ltd, Kapra.-Pragathi Diagnostic , Kapra.- SL Diagnostic and Speciality Clinic, Kapra.

Turnover:About 6900 crores from single manufacturing units in Hyderabad. 39% rise in its 1st quarter 2009-2010, revenues at Rs. 1,818 crores, against Rs. 1,500 crores in the same previous year. : 

Turnover:About 6900 crores from single manufacturing units in Hyderabad. 39% rise in its 1st quarter 2009-2010, revenues at Rs. 1,818 crores, against Rs. 1,500 crores in the same previous year.

Growth over 20 yearsThe company is growing by 39% and improving EBITA by 50%. The profitability has rose by 44%. : 

Growth over 20 yearsThe company is growing by 39% and improving EBITA by 50%. The profitability has rose by 44%.

Thank you : 

Thank you